Brokerages Anticipate Bellicum Pharmaceuticals, Inc. (BLCM) Will Post Earnings of -$0.72 Per Share
Equities research analysts expect Bellicum Pharmaceuticals, Inc. (NASDAQ:BLCM) to report earnings of ($0.72) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Bellicum Pharmaceuticals’ earnings, with estimates ranging from ($0.76) to ($0.63). Bellicum Pharmaceuticals reported earnings per share of ($0.66) during the same quarter last year, which would suggest a negative year-over-year growth rate of 9.1%. The company is scheduled to report its next earnings results on Wednesday, November 8th.
According to Zacks, analysts expect that Bellicum Pharmaceuticals will report full year earnings of ($3.00) per share for the current year, with EPS estimates ranging from ($3.09) to ($2.81). For the next year, analysts anticipate that the business will post earnings of ($2.86) per share, with EPS estimates ranging from ($3.18) to ($2.55). Zacks Investment Research’s EPS averages are an average based on a survey of analysts that cover Bellicum Pharmaceuticals.
Bellicum Pharmaceuticals (NASDAQ:BLCM) last announced its earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($0.74) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.65) by ($0.09). Bellicum Pharmaceuticals had a negative return on equity of 70.74% and a negative net margin of 17,957.31%. During the same quarter in the prior year, the business posted ($0.61) EPS.
Several equities research analysts have issued reports on the company. ValuEngine raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Monday, September 18th. Jefferies Group LLC reaffirmed a “buy” rating and set a $16.00 price target on shares of Bellicum Pharmaceuticals in a report on Thursday, September 14th. BidaskClub raised Bellicum Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Friday, August 25th. Raymond James Financial, Inc. set a $18.00 price target on Bellicum Pharmaceuticals and gave the company a “buy” rating in a report on Wednesday, August 9th. Finally, Wells Fargo & Company reaffirmed an “outperform” rating and set a $31.00 price target on shares of Bellicum Pharmaceuticals in a report on Tuesday, June 27th. Two analysts have rated the stock with a sell rating, one has issued a hold rating and five have issued a buy rating to the stock. The stock presently has a consensus rating of “Hold” and a consensus price target of $26.20.
In related news, VP Ken Moseley sold 13,823 shares of the firm’s stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $12.26, for a total value of $169,469.98. Following the transaction, the vice president now owns 14,314 shares in the company, valued at $175,489.64. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider David M. Spencer sold 10,000 shares of the firm’s stock in a transaction on Monday, July 10th. The stock was sold at an average price of $11.54, for a total value of $115,400.00. The disclosure for this sale can be found here. Insiders have sold a total of 24,260 shares of company stock worth $290,048 in the last quarter. Company insiders own 18.77% of the company’s stock.
Several hedge funds and other institutional investors have recently modified their holdings of the stock. California State Teachers Retirement System increased its position in shares of Bellicum Pharmaceuticals by 16.7% in the second quarter. California State Teachers Retirement System now owns 48,146 shares of the biopharmaceutical company’s stock worth $562,000 after purchasing an additional 6,900 shares during the period. The Manufacturers Life Insurance Company increased its position in shares of Bellicum Pharmaceuticals by 26.6% in the second quarter. The Manufacturers Life Insurance Company now owns 22,319 shares of the biopharmaceutical company’s stock worth $261,000 after purchasing an additional 4,684 shares during the period. State Street Corp increased its position in shares of Bellicum Pharmaceuticals by 16.6% in the second quarter. State Street Corp now owns 416,966 shares of the biopharmaceutical company’s stock worth $4,872,000 after purchasing an additional 59,321 shares during the period. Goldman Sachs Group Inc. increased its position in shares of Bellicum Pharmaceuticals by 223.5% in the second quarter. Goldman Sachs Group Inc. now owns 138,000 shares of the biopharmaceutical company’s stock worth $1,612,000 after purchasing an additional 95,336 shares during the period. Finally, HighTower Advisors LLC bought a new position in shares of Bellicum Pharmaceuticals in the second quarter worth $448,000. Institutional investors own 55.73% of the company’s stock.
Bellicum Pharmaceuticals (BLCM) opened at 11.55 on Friday. Bellicum Pharmaceuticals has a 12 month low of $7.41 and a 12 month high of $23.11. The company’s market cap is $383.76 million. The company’s 50-day moving average is $9.61 and its 200-day moving average is $11.71.
About Bellicum Pharmaceuticals
Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Stock Ratings for Bellicum Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellicum Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.